Toxicity and outcome of pelvic IMRT for node-positive prostate cancer;Nebenwirkungen und Ergebnisse einer Becken-IMRT nodal-positiver Prostatakarzinome

Strahlentherapie und Onkologie

Volumn 188, Issue 11, 2012, Pages 982-989

  Muller A C ^a   Lutjens J ^a   Alber, M ^a   Eckert, F ^a   Bamberg, M ^a   Schilling, D ^a   Belka, C ^b   Ganswindt, U ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Nodal boost; Pelvic IMRT; Pelvis; Prostate cancer; Radiotherapy, intensity modulated

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER SPECIFIC SURVIVAL; CLINICAL ARTICLE; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; SEMINAL VESICLE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER;

EID: 84867951043     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0169-1     Document Type: Article

References (50)

1. (NCCN) NCCN (2011) Prostate cancer. NCCN Clinical Practice Guidelines in Oncology. Vol Version 4.2011: http://www.nccn.org. MS-18
2. Aizer AA, Yu JB, McKeon AM et al (2009) Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 75:1344-1349
3. Alongi F, Fiorino C, Cozzarini C et al (2009) IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93:207-212
4. Arcangeli S, Saracino B, Petrongari MG et al (2007) Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84:148-155
5. Ashman JB, Zelefsky MJ, Hunt MS et al (2005) Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63:765-771
6. Bayley A, Rosewall T, Craig T et al (2010) Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer. Int J Radiat Oncol Biol Phys 77:477-483
7. Bayouth JE, Pena J, Culp L et al (2008) Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients. Med Dosim 33:180-190
8. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103-106
9. Bolla M, Descotes JL, Artignan X et al (2007) Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int 100(Suppl 2):44-47
10. Briganti A, Karnes RJ, Da Pozzo LF et al (2011) Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 59:832-840
11. Chung HT, Xia P, Chan LW et al (2009) Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys 73:53-60
12. Cozzarini C, Fiorino C, Di Muzio N et al (2007) Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol 84:164-170
13. Da Pozzo LF, Cozzarini C, Briganti A et al (2009) Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55:1003-1011
14. Deville C, Both S, Hwang WT et al (2011) Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 78:763-772
15. Deville C, Vapiwala N, Hwang WT et al (2011) Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys (Epub ahead of print)
16. Engels B, Soete G, Tournel K et al (2009) Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat 8:353-359
17. Eschmann SM, Pfannenberg AC, Rieger A et al (2007) Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 46:161-168
18. Fiorino C, Alongi F, Perna L et al (2009) Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 75:29-35
19. Fonteyne V, De Gersem W, De Neve W et al (2009) Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys 75:1013-1020
20. Ganswindt U, Paulsen F, Corvin S et al (2007) Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 67:347-355
21. Ganswindt U, Schilling D, Muller AC et al (2011) Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys 79:1364-1372
22. Garcia JR, Soler M, Blanch MA et al (2009) PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer. Rev Esp Med Nucl 28:95-100
23. Geier M, Astner ST, Duma MN et al (2012) Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol 188:410-416
24. Goldner G, Potter R (2008) Radiotherapy in lymph node-positive prostate cancer patients - a potential cure? Single institutional experience regarding outcome and side effects. Front Radiat Ther Oncol 41:68-76
25. Goldner G, Potter R, Kranz A et al (2011) Healing of late endoscopic changes in the rectum between 12 and 65 months after external beam radiotherapy. Strahlenther Onkol 187:202-205
26. Guerrero Urbano T, Khoo V, Staffurth J et al (2010) Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol) 22:236-244
27. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681-1686
28. Hong TS, Tome WA, Jaradat H et al (2006) Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncol 45:717-727
29. John SS, Zietman AL, Shipley WU et al (2008) Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys 71:43-47
30. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
31. Leitlinienprogramm Onkologie der AWMW DKeVu, e.V DK (2011) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. German S3-Guideline 2011;Version 2.0-1. Aktualisierung 1-236
32. McCammon R, Rusthoven KE, Kavanagh B et al (2009) Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 75:413-420
33. Meijer HJ, Debats OA, Kunze-Busch M et al (2012) Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer. Int J Radiat Oncol Biol Phys 82:175-183
34. Messing EM, Manola J, Sarosdy M et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788
35. Messing EM, Manola J, Yao J et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479
36. Muren LP, Wasbo E, Helle SI et al (2008) Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences. Int J Radiat Oncol Biol Phys 71:1034-1041
37. Perna L, Alongi F, Fiorino C et al (2010) Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy. Radiother Oncol 97:71-75
38. Pervez N, Small C, MacKenzie M et al (2010) Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 76:57-64
39. Pinkawa M, Piroth MD, Holy R et al (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479-484
40. Sanguineti G, Endres EJ, Parker BC et al (2008) Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol 47:301-310
41. Schilling D, Schlemmer HP, Wagner PH et al (2008) Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 102:446-451
42. Schumacher MC, Burkhard FC, Thalmann GN et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54:344-352
43. Sheets N, Goldin GH, Meyer AM et al (2011) Comparative long-term morbidity of intensity modulated vs. conformal radiation therapy (RT) for prostate cancer: a SEER-medicare analysis. Int J Radiat Oncol Biol Phys 78:43
44. Su AW, Jani AB (2007) Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol 30:215-219
45. Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph node-positive prostate cancer. Cancer 106:2531-2539
46. Tward JD, Shrieve CD (2010) Radiotherapy is correlated with superior survival in clinically node positive prostate cancer. Int J Radiat Oncol Biol Phys 78:31
47. Weckermann D, Goppelt M, Dorn R et al (2006) Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 97:1173-1178
48. Weidner AM, Lin EN van, Dinter DJ et al (2011) Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse. Strahlenther Onkol 187:206-212
49. Wurschmidt F, Petersen C, Wahl A et al (2011) [18F]fluoroethylcholine- PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 6:44-51
50. Zurlo A, Collette L, Tienhoven G van et al (2002) Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. Eur Urol 42:125-132